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Gentamicin C complex is amixture of aminoglycoside
antibiotics used worldwide to treat severe Gram-
negative bacterial infections. Despite its clinical
importance, the enzymology of its biosynthetic
pathway has remained obscure. We report here
insights into the four enzyme-catalyzed steps that
lead fromthefirst-formedpseudotrisaccharidegenta-
micin A2 to gentamicin X2, the last common interme-
diate for all components of the C complex. We have
used both targeted mutations of individual genes
and reconstitution of portions of the pathway in vitro
to show that the secondary alcohol function at C-300
of A2 is first converted to an amine, catalyzed by the
tandem operation of oxidoreductase GenD2 and
transaminase GenS2. The amine is then specifically
methylated by the S-adenosyl-L-methionine (SAM)-
dependent N-methyltransferase GenN to form genta-
micin A. Finally, C-methylation at C-400 to form
gentamicinX2 is catalyzedby the radical SAM-depen-
dent and cobalamin-dependent enzyme GenD1.
INTRODUCTION
Gentamicins are clinically valuable aminoglycoside antibiotics
isolated as gentamicin C complex, a mixture of five components
(Figure 1), from the filamentous bacterium Micromonospora
echinospora. Gentamicins are protein synthesis inhibitors used
to combat Gram-negative bacterial infections. They are also be-
ing explored in other therapeutic areas (Hainrichson et al., 2008;
Linde and Kerem, 2008; Cuccarese et al., 2013). However, gen-
tamicins carry a serious risk of kidney damage and hearing loss
(Bockenhauer et al., 2009) which limits their utility, and it is there-
fore encouraging that evidence is available that an individual
component of the gentamicin mixture may have lower toxicity
(Sandoval et al., 2006; Kobayashi et al., 2008). This makes theChemistrygentamicin biosynthetic pathway an attractive target for reengin-
eering to favor a specific component.
Gentamicins are modified sugars, characteristically contain-
ing an unusual aminocyclitol ring (2-deoxystreptamine, 2-DOS
[1]) (Houghton et al., 2010; Park et al., 2013). The outlines of
the gentamicin pathway have been known for some time (Testa
and Tilley, 1975, 1976; Kase et al., 1982a, 1982b), and in the
wake of the comprehensive sequencing of aminoglycoside
biosynthetic gene clusters (Ota et al., 2000; Unwin et al., 2004;
Kharel et al., 2004a, 2004b, 2004c; Huang et al., 2005; Subba
et al., 2005; Aboshanab, 2005; Hong et al., 2009) rapid progress
has beenmade in identifying the enzymatic steps that lead to the
2-DOS scaffold, and thence to the pseudodisaccharide parom-
amine (2) (Llewellyn and Spencer, 2006; Thibodeaux et al.,
2008; Kudo and Eguchi, 2009; Kudo et al., 2009) and the pseu-
dotrisaccharide gentamicin A2 (3) (Park et al., 2008) (Figure 1).
This has enabled a sharper focus on those genes likely to govern
the later steps of gentamicin biosynthesis.
We (Guo et al., 2014) and others (Karki et al., 2012; Hong and
Yan, 2012; Li et al., 2013) have used specific gene deletions
to probe the identity of the enzymes that act on gentamicin X2
(4), partitioning this intermediate between a methylated branch
that gives rise via G418 (5) to gentamicin components C2a, C2,
and C1 and an unmethylated branch that gives rise to C1a
and C2b (Figure 1). The cluster contains multiple, mutually
homologous genes for methyltransferases, oxidoreductases,
and aminotransferases with potential for overlapping substrate
specificities, but by combining analysis of specific gene dele-
tions with in vitro reconstitution of the enzymes involved in dehy-
drogenation/transamination of G418 (5) (Guo et al., 2014) it has
been possible to deconvolute the specific roles of some of the
individual genes in this final stage of the pathway. Also, Liu
and colleagues have demonstrated the activity in vitro of
GenK, which methylates 4 to produce 5, and have confirmed
that it is a cobalamin-dependent radical S-adenosyl-L-methio-
nine (SAM) enzyme (Kim et al., 2013).
Here we present a similar in vivo and in vitro analysis to define
the enzymology of the pathway from the first pseudotrisacchar-
ide 3 to the last common precursor of the gentamicin C complex,
gentamicin X2 (4). It has already been established that disruption& Biology 22, 251–261, February 19, 2015 ª2015 The Authors 251
Figure 1. The Pathway to Gentamicin X2
The roles revealed in this study of GenD2, GenS2, GenN, and GenD1 are highlighted in orange. Shunt products of GenK are shown in blue. For details, see the
text. A2 (3): gentamicin A2; DOA2 (8): 300-dehydro-300-oxo-gentamicin A2; DAA2 (9): 300-dehydro-300-amino-gentamicin A2; X2 (4): gentamicin X2; A2e (7):
60-methylgentamicin A2; Ae (6): 60-methylgentamicin A. Carbon numbering is shown with the structure of 3.
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of the gene genD1, also known as gntE (Unwin et al., 2004) or
gtmI (Kharel et al., 2004c), by a thiostrepton resistance gene
(tsr) leads to accumulation of 3 (Figure 1) (Kim et al., 2008). These
authors interpreted their result as meaning that GenD1 catalyzes
N-methylation of the 300-amino group in 3; but several alternative
explanations of this result are possible, especially as polar ef-
fects on the downstream genS2 gene were not ruled out. By
analysis of the gentamicin-related metabolites accumulated in
strains bearing single and multiple specific gene deletions, by
following the bioconversion of specific intermediates fed to
suchmutants, and by reconstituting all of the steps using purified
recombinant enzymes, we demonstrate here that in fact the
respective (and essential) catalytic contributions of the dehydro-
genase GenD2, the pyridoxal phosphate-dependent amino-
transferase GenS2, the SAM-dependent N-methyltransferase
GenN, and the radical SAM-dependent C-methyltransferase
GenD1 are as shown in Figure 1. We also provide evidence for
the ability of GenK to act precociously on 3 and gentamicin A
(6) (Figure 1) to generate shunt metabolites.
RESULTS
GenD2, GenS2, and GenN Are Essential for Conversion
of Gentamicin A2 into Gentamicin A
The gene genD2 (also known asgntC [Unwin et al., 2004] or gtmC
[Kharel et al., 2004c]) is a candidate to act on 3 because it is pre-
dicted to encode an NAD(P)H-linked dehydrogenase with signif-
icant sequence identity to Sis12, KanD2, and TobD2, enzymes
catalyzing similar reactions in other aminoglycoside pathways.
To investigate the proposed role of the GenD2 dehydrogenase
in the specific oxidation of 3 at the C-300-hydroxyl, this gene
was knocked out by targeted in-frame deletion of a 930 bp inter-
nal fragment (Figure S1A available online). The mutant was
confirmed by PCR and Southern hybridization (Figure S1A).
Liquid chromatography/electrospray ionization/high-resolution
mass spectrometry (LC-ESI-HRMS) analysis confirmed that
fermentation of this mutant produces elevated levels of 3, but
no other gentamicins normally seen in the wild-type (Figures
2C and S2A). A second new species was also observed, which
from LC-ESI-HRMS and tandem mass spectrometry (MS/MS)
analysis (Figure S2B) appears to represent a derivative of 3meth-
ylated at theC-60 position. This specieswas first detected by Kim
et al. (2008) as a by-product of their genD1 disruptant and was
named by them gentamicin A2e (7; Figure 1) but not character-
ized. Complementation of the DgenD2 mutant, carried out by
using plasmid pWHU184 containing genD2 under the control of
the PermE* promoter (Figure S1G), restored the production of
gentamicin C complex and of various intermediates to wild-
type levels (Figure 2G). Chemical complementation of the
DgenD2 mutant by feeding 6 also similarly restored production
of gentamicin C complex (Figure S3C), confirming the primary
role of GenD2 in the section of the pathway between 3 and 6.
Recent in vivo (Kim et al., 2008; Hong and Yan, 2012; Guo
et al., 2014) and in vitro (Kim et al., 2013) work has unequivocally
established that methylation at the C-60 position is normally car-
ried out on 4 by the SAM-dependent methyltransferase GenK.
We suspected therefore that the appearance of 7 in our DgenD2
mutant was a consequence of the action of GenK in the absence
of its normal substrate. To test this, a double mutant deleted in-Chemistryframe in both genD2 and genK was constructed (Figure S1C).
LC-ESI-HRMS analysis confirmed that this mutant accumulated
3 but not 7 (Figure 2E). Complementation of the DgenD2DgenK
strain with plasmid pWHU67 containing genK under the control
of the PermE* promoter (Figure S1K), restored the coproduction
of the shunt product 7 (Figure 2I).
GenS2, the product of the unassigned gene genS2 (also
known as gntF [Unwin et al., 2004] or gtmD [Kharel et al.,
2004c]) is a plausible candidate to partner GenD2 in amination
at C-300 because it is predicted to encode a pyridoxal phos-
phate-dependent aminotransferase with significant sequence
identity to Sis15, KanS2, and TobS2, enzymes catalyzing similar
reactions in other aminoglycoside pathways. Accordingly, this
gene was knocked out by targeted in-frame deletion and the
mutant was confirmed by PCR and Southern hybridization (Fig-
ure S1B). LC-ESI-HRMS analysis confirmed that fermentation of
this mutant only produced 3 and 7 (Figure 2D). Complementation
of the DgenS2 mutant, carried out by using plasmid pWHU115
containing genS2 under the control of the PermE* promoter (Fig-
ure S1H), restored the production of gentamicin C complex and
of various intermediates to wild-type levels (Figure 2H). Chemical
complementation of the DgenS2 mutant by feeding 6 also simi-
larly restored production of gentamicin C complex (Figure S3D),
confirming that the genS2 gene, like genD2, is essential and acts
exclusively in the section of the pathway between 3 and 6,
consistent with a specific role in partnering GenD2 to accomplish
amination at C-300. Also, the shunt product gentamicin 7 was not
present in a DgenS2DgenK double mutant (Figures 2F and S1D)
but its appearance was restored by complementation in trans by
constitutive expression of genK (Figures 2J and S1L). The pre-
sumed intermediate in amination at C-300 is 300-dehydro-300-
oxo-gentamicin A2 (DOA2 [8]; Figure 1), and this was not
detected in the DgenS2 or DgenS2DgenK mutants. Either the
compound is unstable, or the GenD2-catalyzed oxidation does
not proceed if the ketone product is not continuously removed
(see below).
The third and final step between 3 and the known intermediate
6 involves N-methylation of the newly introduced 300-amino
group in the garosamine ring (Figure 1). Of the several predicted
methyltransferase genes in the gentamicin gene cluster, genN
(GI: 85814038; Aboshanab, 2005) is an attractive candidate for
this role. It is predicted to encode a conventional SAM-depen-
dent methyltransferase, and its closest known homolog (90%
sequence identity) is Sis30 in the cluster for sisomicin ([19];
Hong et al., 2009), a closely related aminoglycoside which re-
quires a similar N-methylation (Supplemental Experimental Pro-
cedures). The gene clusters for the aminoglycosides kanamycin
(11) and tobramycin (12), which do not contain a 300-N-methyl
group (Supplemental Experimental Procedures), contain no
gene homologous to GenN.
GenN was knocked out by targeted in-frame deletion of a
933 bp internal fragment (Figure S1E). LC-ESI-HRMS analysis
revealed that fermentation of this mutant produced 3 and 7 (Fig-
ure 2L), together with small amounts of a compoundwith the pre-
dicted mass of 300-dehydro-300-amino-gentamicin A2 (DAA2 [9];
Figures 1 and S2C), but none of the gentamicin C components
was detected. Trace amounts of demethylgentamicin C1, deme-
thylgentamicin C2, and demethylgentamicin C1awere observed.
The fragmentation profiles of these demethylgentamicins& Biology 22, 251–261, February 19, 2015 ª2015 The Authors 253
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indicate that they lack a methyl group in the garosamine ring.
Complementation of the DgenN mutant, carried out by using
plasmid pWHU68 containing genN under the control of the
PermE* promoter (Figure S1I), restored the production of genta-
micin C complex and of various intermediates to wild-type levels
(Figure 2N). Chemical complementation of the DgenN mutant by
feeding gentamicin A restored production of gentamicin C com-
plex (Figure S3E), confirming that the genN gene, like genD2
and genS2, is essential and acts exclusively in the section of
the pathway between 3 and 6, consistent with a specific role in
N-methylation of the C-300 amino group.
The remaining step in the conversion of 3 to 4 is the C-methyl-
ation of 3 at the C-400 position (Figure 1). The gene genD1 (also
known as gntE (Unwin et al., 2004) or gtmI (Kharel et al.,
2004c), previously assigned as an oxidoreductase/methyltrans-
ferase (Kim et al., 2008), is a strong candidate to encode this
methyltransferase, because it shows significant sequence iden-
tity to authentic cobalamin-dependent and radical SAM-depen-
dent methyltransferases (Kim et al., 2013). Accordingly, the
genD1 gene was knocked out by in-frame deletion of an
1,851 bp internal fragment (Figure S1F). In contrast to previous
findings based on disruption of the genD1 gene (Kim et al.,
2008), LC-ESI-HRMS analysis showed that fermentation of this
mutant produced not only 3 and 7 but also 6 (Figures 2K and
S2D). The most abundant peak was a new species with the
mass of 4 but with a different retention time and MS/MS frag-
mentation pattern (Figure S2E). The appearance of this species
(called here gentamicin Ae [10]) is consistent with GenK-cata-
lyzed methylation of 6 at C-60 in the absence of its normal genta-
micin X2 (4) substrate. Complementation of the DgenD1 mutant
in trans, using a plasmid housing genD1 under a constitutive pro-
moter (Figure S1J), restored wild-type levels of gentamicins (Fig-
ure 2M). Chemical complementation of the DgenD1 mutant by
feeding 6 did not restore production of gentamicin C complex
(Figure S3F), but complementation by feeding with 5 did restore
the production of gentamicin C2a, C2, and C1, the products in
the ‘‘methylated branch’’ (Figure S3G). This confirmed that the
genD1 gene is essential and acts exclusively in the conversion
of 6 to 4, consistent with a specific role in C-methylation at the
C-400 position. It appears likely that in the disruption mutant pre-
viously studied (Kim et al., 2008), there was a deleterious polar
effect on the downstream genS2 gene, which would account
for the lack of accumulation of 6 in that study.
Purified Recombinant GenD2, GenS2, and GenN
Together Catalyze Successive 300-Oxidation,
Transamination, and N-Methylation of Gentamicin A2 to
Form Gentamicin A
To obtain direct evidence for the catalytic roles of GenD2,
GenS2, and GenN, we turned to in vitro reconstitution experi-
ments, starting with gentamicin A2 (3). This substrate was puri-
fied from fermentation extracts of the DgenS2DgenK strain of
M. echinospora (Figure 2F), and its identity was confirmed byFigure 2. Production of Gentamicins by Micromonospora echinospora
LC-ESI-HRMS total ion current traces of (A) gentamicin standard; and of mutant fe
mutant; (E) DgenD2DgenK mutant; (F) DgenS2DgenK mutant; (G) DgenD2::gen
DgenS2DgenK::genKmutant; (K) DgenD1 mutant; (L) DgenN mutant; (M) DgenD1
Figure 1.
ChemistryLC-HRMS. GenD2, GenS2, and GenN were each expressed in
Escherichia coli as soluble N-His6-tagged proteins and purified
to near homogeneity (Figure S4A). The molecular weights of
the proteins as analyzed by LC-MS were in agreement with the
calculated values assuming loss of the N-terminal methionine:
38,533 Da for GenD2 (calculated 38,539 Da); 48,820 Da
for GenS2 (calculated 48,826.5 Da); and 37,218 Da for GenN
(calculated 37,221.8 Da), respectively. Adventitious N-gluconyl
modification (+178 Da) (Geoghegan et al., 1999) was also seen
with these proteins.
First, the predicted dehydrogenase GenD2 was incubated
with 3, and either NAD+ or NADP+ as redox cofactor, at 30C.
Samples were analyzed using LC-ESI-HRMS after 10 min,
60 min, 90 min, and overnight incubation. However, no DOA2
(8) was detected, even after overnight incubation. Addition of
the aminotransferase GenS2, and L-glutamate as amino donor,
also failed to reveal any of the expected DAA2 (9). In contrast,
when all three enzymes (GenD2, GenS2, and GenN) were pre-
sent, as well as NAD+, L-glutamate, and SAM (as a methyl
donor), essentially complete (>96%) conversion of 3 (Figure 3A)
to 6 (Figure 3B) was achieved within 10 min at 30C. The identity
of the product was confirmed by LC-ESI-HRMS analysis, and
comparison with authentic 6: [M+H]+ m/z = 469.2498 (1.28
ppm) and [M + Na]+ m/z = 491.2319 (1.02 ppm) (Figure 3B).
Reactions lacking any one of the three enzymes did not yield
any product. These results strongly support the hypothesis
that the 300-modifications on 3 leading to 6 formation are indeed
catalyzed by the coupled activities of GenD2, GenS2, and
GenN. It is reasonable to speculate that the activities of
GenD2 and GenS2 may be inhibited by very low levels of their
products and that subsequent 300-methylation by GenN allevi-
ates this product inhibition.
The Aminoglycosides Kanamycin B and Tobramycin
Are Deaminated by GenS2 and GenD2 and Methylated
by GenN
To help confirm the respective roles of GenD2 and GenS2, kana-
mycin B (11) and tobramycin (12) were used. These aminoglyco-
side antibiotics are close structural analogs of DAA2 (9), and both
possess an unmethylated 300-amino group, so they could be
tested as surrogate substrates for 300-deamination, the reverse
of the reaction normally catalyzed by GenS2/GenD2. In these
assays, using 2-oxoglutarate as the amino acceptor, LC-ESI-
HRMS analysis showed that GenS2 catalyzed low-level deami-
nation of both compounds. The change could be localized to
the kanosamine ring, consistent with the production, respec-
tively, of trace amounts of 300-deamino-300-oxo-kanamycin B
(13; [M + H]+m/z 483.2287, [M + Na]+m/z 505.2113) (Figure S5B)
and 300-deamino-300-oxo-tobramycin (14; [M + H]+m/z 467.2342)
(Figure S5F). In contrast, in the presence of GenS2 and GenD2
(and either NADH or NADPH) essentially quantitative yields
were obtained of, respectively, 300-deamino-300-hydroxy-kana-
mycin B (15; [M + H]+ m/z 485.2443, [M + Na]+ m/z 507.2263)Mutants
rmentation culture extracts from (B) wild-type; (C) DgenD2mutant; (D) DgenS2
D2 mutant; (H) DgenS2::genS2 mutant; (I) DgenD2DgenK::genK mutant; (J)
::genD1mutant; (N) DgenN::genNmutant. For the structure of metabolites, see
& Biology 22, 251–261, February 19, 2015 ª2015 The Authors 255
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Figure 3. Enzymatic One-Pot Conversion of Gentamicin A2 to Gentamicin A
LC-ESI-HRMS selective ion monitoring was carried out on (A) [M + H]+ (m/z 456) and [M + Na]+ (m/z 478) ions of gentamicin A2 (3); (B) [M + H]+ (m/z 469) and
[M + Na]+ (m/z 491) ions of gentamicin A (6), produced by the coupled action of GenD2, GenS2, and GenN on gentamicin A2 (3). MS/MS fragments from the
[M + H]+ (m/z 456) and [M + H]+ (m/z 469) ions are shown as insets.(Figure S5C) and 300-deamino-300-hydroxy-tobramycin (16; [M +
H]+ m/z 469.2496, [M + Na]+ m/z 491.2314) (Figure S5G).
11 and 12 were excellent substrates for SAM-dependent
methylation by GenN, the reaction being complete after 1 hr at
30C. For kanamycin B GenN showed kcat = 1.93 ± 0.1 s
1 and
Km = 34 ± 3.8 mM (see Supplemental Experimental Procedures
for assay details). LC-ESI-HRMS analysis confirmed that methyl-
ation in both cases occurred specifically on the kanosamine
ring, consistent with the formation, respectively, of 300-N-
methyl-kanamycin B (17; [M + H]+ m/z 498.2761 (1.81 ppm),
[M + Na]+ m/z 520.2582 (1.35 ppm)) (Figure S5D) and 300-N-
methyltobramycin (18; [M + H]+ m/z 482.2814 (1.45 ppm),
[M + Na]+ m/z 504.2633 (1.39 ppm)) (Figure S5H). In contrast,
GenN had no effect on 6, 4, or 5, all of which are gentamicin in-
termediates already methylated at the 300-N position. These re-
sults further confirm the 300-oxidoreductase activity of GenD2,
the 300-aminotransferase activity of GenS2, and the 300-N-methyl-
ation activity of GenN. Purified 15, when used as substrate for
the forward reaction, gave neither detectable 13 with GenS2
alone nor detectable 11 with GenS2 and GenD2 together. How-256 Chemistry & Biology 22, 251–261, February 19, 2015 ª2015 Theever, 15 was smoothly converted by GenS2, GenD2, and GenN
into 17.
The Radical SAM Methyltransferase GenD1 Catalyzes
Cobalamin-Dependent Methylation of Gentamicin A to
Produce Gentamicin X2
The putative radical SAM enzyme GenD1 is one of two such
intriguing enzymes in the gentamicin pathway, the other being
GenK, which catalyzes C-methylation of gentamicin X2 (4) at the
C-60 position (Kim et al., 2013). Like GenK, a putative cobal-
amin-dependent radical SAM C-methyltransferase, and like
Sis14 from the gene cluster for the closely related aminoglycoside
sisomicin (19; Supplemental Experimental Procedures), GenD1
houses a sequence motif (Cx4Cx2C) highly similar to the
conserved Cx3Cx2C binding site for the [4Fe-4S] iron-sulfur clus-
ter found in the radical SAM superfamily (Kim et al., 2013). The
iron-sulfur cluster would mediate homolysis of SAM, triggering
formation of a gentamicin substrate radical which in turn recruits
a methyl group from methylcobalamin. Important preliminary evi-
dence has recently beenpresented for the in vitro activity ofGenK,Authors
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Figure 4. C-Methylation of Gentamicin A to
Gentamicin X2 Catalyzed by GenD1
LC-ESI-HRMS selective ion monitoring was car-
ried out on (A) [M + H]+ m/z 483 of the product of
GenD1-catalyzed methylation of gentamicin A (6);
(B) [M + H]+ m/z 252 of coproduced 50-dAdo (20);
(C) MS and MS/MS spectra of gentamicin A (6); (D)
MS and MS/MS spectra of gentamicin X2 (4).
Different high-performance liquid chromatography
conditions were used for detection of gentamicin
X2 (4) and 50-dAdo (20), respectively, as described
in Supplemental Experimental Procedures. 50-
dAdo, 50-deoxyadenosine; BV, benzyl viologen;
MV, methyl viologen.including the involvement of cobalamin (Kim et al., 2013). GenD1
was accordingly expressed in E. coli as a soluble N-His6-tagged
protein and purified to near homogeneity (Figure S5A). Themolec-
ular weight of purified recombinant GenD1 as determined by LC-
MS analysis was 77,410 Da, consistent with the calculated mass
(77,417.5 Da) of the protein lacking the first methionine. Affinity
purification, buffer exchange to remove imidazole, and reconstitu-
tion of the iron-sulfur cluster were carried out in an anaerobic
chamber to minimize oxidative damage. Purified GenD1 had a
brownish color. After reconstitution of the iron-sulfur cluster in
GenD1 using ferrous ammonium sulfate and sodium sulfide, the
protein solution assumed a gray-black color, as reported for otherChemistry & Biology 22, 251–261,radical SAM-dependent methyltrans-
ferases, and showed a UV-visible ab-
sorbance peak centered on 415 nm (Fig-
ure S4B) as expected for a protein
containing an iron-sulfur cluster (Duin
et al., 1997; Pierrel et al., 2002; Kim et al.,
2013). The color of the protein faded grad-
ually within hours upon exposure to air.
Freshly purified and reconstituted
GenD1 was assayed for its ability to cata-
lyze C-methylation of 6 at the C-400 posi-
tion to yield 4, using conditions previously
found successful for GenK (Kim et al.,
2013). Incubations (12 hr) were carried
out in an anaerobic chamber at 30C
and the reaction mixtures were analyzed
by using LC-ESI-HRMS. Reaction mix-
tures contained commercially available 6
(0.4 mM), SAM (4 mM), dithiothreitol
(DTT) (10 mM) and methylcobalamin
(1 mM) in 50 mM Tris-HCl buffer (pH
8.0). The reactionwas initiated by addition
of GenD1 (50 mM). With sodium dithionite
(4 mM) as the source of electrons, and
with either methyl viologen (MV) or benzyl
viologen (BV) (each at 1 mM) present to
mediate reductive activation of the iron-
sulfur center, only modest (4%–5%)
conversion of 6 to a methylated product
was seen. However, conversion was
increased to 84%–88% when the source
of electrons was NADPH (4 mM) (Fig-ure 4A). The methylated product had a mass consistent with
that of 4: [M + H]+ m/z 483.2650 (2.28 ppm); [M + Na]+ m/z
505.2468 (2.37 ppm). Its MS-MS fragmentation pattern, iden-
tical to that of authentic 4 (Figure 4B), confirmed that the methyl-
ation had occurred as expected on the C-400 position of 6. As
found for GenK, methylcobalamin could be replaced by hydrox-
ocobalamin (14%–18% conversion), suggesting that methylco-
balamin can be regenerated by methyltransfer from SAM during
catalysis. 4was not formed in the absence of either cobalamin or
viologen. Omission of the reconstitution step, or carrying out as-
says under aerobic conditions, gave little or no activity. The for-
mation of 50-deoxyadenosine (20, 50-dAdo) as a reaction productFebruary 19, 2015 ª2015 The Authors 257
Figure 5. Production of 50-Deoxyadenosine
during GenD1-Catalyzed Methylation of
Gentamicin A
LC-ESI-HRMS selective ion monitoring and MS/
MS fragmentation of 50-deoxyadenosine (50-dAdo)
(20), [M + H]+ m/z 252.was also confirmed by LC-ESI-HRMS ([M+H]+ m/z 252.1089
(1.19 ppm)) (Figures 4A and 5), suggesting a similar catalytic
mechanism to that proposed for GenK, in which a 50-dAdo
radical generated via the reductive cleavage of SAM abstracts
a hydrogen from the substrate, leading to the formation of a sub-
strate radical (Kim et al., 2013).
DISCUSSION
The confident application of synthetic biology to reconfigure
gene sets and thus redirect the course of an antibiotic biosyn-
thetic pathway requires an excellent understanding of the under-
lying enzymology. For the biosynthetic pathway to the genta-
micin C complex, an established drug to treat life-threatening
infections caused by Gram-negative bacteria, even the task of
assigning functions to individual gene products involved in the
pathway is not trivial because the cluster contains multiple,
mutually homologous genes for methyltransferases, oxidore-
ductases, and aminotransferases with potential for overlapping
substrate specificities. There are numerous precedents from
other aminoglycoside pathways for enzyme promiscuity or
even dual function (Huang et al., 2007; Fan et al., 2008; Yo-
koyama et al., 2008; Park et al., 2011). From our analysis of the
DgenD2, DgenS2, and DgenN mutants of M. echinospora it is
clear that GenD2 (dehydrogenase), GenS2 (aminotransferase),
and GenN (N-methyltransferase) uniquely govern the replace-
ment of the C-300-hydroxyl group in gentamicin A2 (3) by the
methylamino group of gentamicin X2 (4). No other enzymes in
M. echinospora were able to take over these roles under the
fermentation conditions used, and these enzymes are appar-
ently not required elsewhere in the pathway. The appearance
in these mutants of the shunt metabolite gentamicin A2e (7) is
readily explained by the action of the methyltransferase GenK
on the earlier precursors gentamicin A2 (3) and gentamicin A
(6) in the absence of its normal substrate.
The selective production of gentamicin A2 (3) from the
DgenD2DgenK mutant provided the substrate to study the re-
combinant enzymes in vitro. The in vitro work, in turn, confirmed
the conclusions from the initial analysis of specific gene knock-
outs but importantly also revealed that the GenD2/GenS2-
catalyzed dehydrogenation/amination only proceeds when the
gentamicin A (6) product is removed (byGenN-catalyzedmethyl-
ation) as fast as it is formed. The simplest explanation for this
observation is the relief of product inhibition, a neat way to avoid
unwanted buildup of reactive pathway intermediates. Indirect
confirmation of the likely nature of those intermediates between258 Chemistry & Biology 22, 251–261, February 19, 2015 ª2015 The Authorsgentamicin A2 (3) and gentamicin A (6)
could nevertheless be obtained by study-
ing the reactions in reverse, using as sub-
strate analogs of 6 the structurally relatedaminoglycosides kanamycin B (11) and tobramycin (12), which
each have a free 300-amino group. GenS2 alone did not catalyze
transamination of either substrate but each was efficiently con-
verted into the respective 300-hydroxy-derivative by the joint
action of GenS2 and GenD2. The 300-hydroxy-kanamycin B
(15), when used as a substrate for the forward reaction, behaved
exactly like gentamicin A2 (3): no reaction with GenD2 and
GenS2 unless all three enzymes (GenD2, GenS2, and GenN)
were present, strongly suggesting that the presence of GenN
relieves product inhibition by 13 and 11.
It has been previously suggested (Kim et al., 2008) that GenD1
catalyzes the N-methylation at C-300 of gentamicin A (6), but it is
clear from our present work that GenN governs this step. Rather,
GenD1 can be confidently assigned, on the basis of both in vivo
gene disruption and direct in vitro assay, as the C-methyltrans-
ferase that transforms gentamicin A (6) into gentamicin X2 (4).
After GenK (Kim et al., 2013), GenD1 is the second representa-
tive of this mechanistically intriguing class of cobalamin-depen-
dent radical SAM methyltransferases to be characterized in the
gentamicin pathway. Both these enzymes activate and achieve
substitution at unactivated sp3 C centers. Unlike GenK, which
has required refolding from inclusion bodies after heterologous
expression (Kim et al., 2013), GenD1 is expressed in E. coli as
a soluble protein in excellent yield, which should be helpful in
future mechanistic study of this enzyme.
SIGNIFICANCE
Aminoglycosides, mainly produced by actinobacteria,
constitute a vital clinical asset. Gentamicin in particular is
of continuing interest because of its remarkable potency in
treatingsystemicGram-negative infections, andyetbecause
of the significant known toxicity of the gentamicin complex it
requires constant and expensive individualmonitoring of pa-
tients. The perspective of a safer and less expensive genta-
micin throughadministrationof a single component, or using
asingle component for semisynthesis of anovel derivative, is
therefore very attractive. The work we report here has used
complementary in vivo and in vitro approaches to identify
the four key enzymes that lead from thefirst-formedpseudo-
trisaccharide to gentamicin X2, themost advanced common
precursor of all the components of gentamicin C complex. It
hasconfirmed theactivityof soluble recombinantGenD1asa
cobalamin-dependent radical SAMmethyltransferase in this
pathway, paving the way for detailed mechanistic study of
this intriguing enzyme; and, by more closely defining the
molecular enzymologyof thepathway inM.echinospora, has
brought closer the goal of assembling a defined set of en-
zymes to deliver single gentamicin C components.
EXPERIMENTAL PROCEDURES
Bacterial Strains and Plasmids, Chemicals, and Culture Conditions
E. coli strains NovaBlue and BL21(DE3) (Novagen) were used as cloning and
expression hosts, respectively. For routine cloning E. coli strains were main-
tained in 23 TY medium (tryptone 1.6%, yeast extract 1%, NaCl 0.5%) at
37Cwith appropriate antibiotic selection at the indicated final concentrations:
ampicillin (100 mg/ml), apramycin (50 mg/ml), kanamycin (25 mg/ml), or chloram-
phenicol (25 mg/ml). For E. coli protein expression, Luria-Bertani (LB) medium
(1% tryptone, 0.5%yeast extract, 1%NaCl) was used at 37Cwith appropriate
antibiotic selection at the indicated final concentrations: tetracycline (15 mg/ml)
for NovaBlue cells, kanamycin (50 mg/ml) for cells harboring the recombinant
pET28a(+) plasmids, and carbenicillin (100 mg/ml) for plasmid pDB1282,
containing essential genes for biosynthesis of the iron-sulfur cluster (Zheng
et al., 1998). Ferrous ammonium sulfate, LB medium, imidazole, NaCl, and
Tris base were purchased from Fisher Scientific. Restriction endonucleases,
Pfu DNA polymerases, and T4 DNA ligase were from Fermentas (Thermo Sci-
entific). Oligonucleotide primers were synthesized by Invitrogen Life Technolo-
gies. Gentamicin A (6), gentamicin X2 (4), and kanamycin B (11) were products
from Toku-E. G418 used for feeding studies was from Gibco. Amino acids, hy-
droxocobalamine, methylcobalamine (MeCbl), MV, BV, SAM, sodium dithion-
ite, sodium sulfide, and tobramycin (12) were obtained from Sigma-Aldrich.
M. echinospora ATCC15835 wild-type and mutants were grown on ATCC
172 medium (glucose 1%, yeast extract 0.5%, soluble starch 2%, N-Z amine
0.5%, CaCO3 0.2%) at 28
C for genomic DNA isolation and cultivation. For
aminoglycoside production, the seed culture was shaken at 220 rpm in liquid
ATCC 172medium at 28C for 2 days and then used to initiate the fermentation
culture (5% inoculum) in fermentation medium (Soybean powder 2.0%,
peptone 0.1%, glucose 0.3%, (NH4)2SO4 0.03%, CaCO3 0.3%, KNO3
0.03%, CoCl2 5 ppm) shaken at 220 rpm and at 28
C for 5 days. For feeding
experiments, filter-sterilized compounds (150 mg/ml) were added to the
fermentation medium before inoculation.
Isolation and Analysis of Gentamicin and Intermediates
The fermentation broth was adjusted to pH 2.0 with concentrated HCl. The
cultures were agitated for 2 hr on a laboratory rocker and then centrifuged at
5000 g for 10 min at 4C. Each supernatant was applied to a column of
1.5 g DOWEX 50WX8-200 ion-exchange resin preconditioned with 50 ml
acetonitrile followed by 50 ml 3 4 distilled-deionized water. The column was
washed with 15 ml of water and then aminoglycosides were eluted with
15 ml of 1 M ammonium hydroxide. The eluate was freeze-dried, the residue
was dissolved in 1 ml of water, and a sample was subjected to high-perfor-
mance liquid chromatography-HRMS analysis.
Construction of Gene Disruption Plasmids
For in-frame deletion, DNA fragments flanking each target gene were amplified
from the genomic DNA of M. echinospora ATCC15835 using Phusion DNA
polymerase (New England Biolabs). The PCR products were each cloned
into pUC18, then cut out and cloned together into the Streptomyces-E. coli
shuttle vector pYH7 (Sun et al., 2008) to obtain the following gene disruption
plasmids: pWHU6 (for DgenD2), pWHU21 (for DgenS2), pYH289 (for DgenN),
and pYH287 (for DgenD1). For construction of the DgenD2DgenK and
DgenS2DgenK double mutants, pWHU1 (Guo et al., 2014) was employed for
genK in-frame deletion. All plasmids were verified by sequencing.
Construction of Gene Complementation Plasmids
Complementation plasmids were prepared by cloning genD2, genS2, genN,
genD1, and genK, respectively, into pWHU77 (a plasmid derived from
pIB139 [Wilkinson et al., 2002; Del Vecchio et al., 2003] with the apramycin
resistance gene replaced by a thiostrepton resistance gene) under the control
of the PermE* promoter (Figure S1). The PCR products were inserted into
pWHU77 between the NdeI and EcoRI sites to generate pWHU184,
pWHU115, pWHU68, pWHU66, and pWHU67. After sequence confirmation,Chemistrythese plasmids were introduced individually into DgenD2 (pWHU184),
DgenS2 (pWHU115), DgenN (pWHU68), DgenD1 (pWHU66), DgenD2DgenK
(pWHU67), and DgenS2DgenK (pWHU67) by conjugation. Complemented
exconjugants were verified based on thiostrepton resistance and confirmed
by PCR (Figure S1).
Targeted In-Frame Gene Deletion
To create individual in-frame deletion mutants of genD2, genS2, genN,
and genD1, the corresponding plasmid pWHU6, pWHU21, pYH289, and
pYH287 was introduced into the wild-type strain by conjugation from E. coli
ET12567/pUZ8002 (MacNeil et al., 1992) on ABB medium (soytone 0.5%, sol-
uble starch 0.5%, CaCO3 0.3%, MOPS 0.21%, FeSO4 0.0012%, thiamine-HCl
0.001%, agar 3%) with addition of 10 mM MgCl2 solution. After 10 hr incuba-
tion at 28C, the exconjugants were selected with nalidixic acid (12.5 mg/ml)
and apramycin (12.5 mg/ml). Exconjugants were transferred onto ABBmedium
containing nalidixic acid (25 mg/ml) and apramycin (25 mg/ml). To promote a
second crossover, these mutants were propagated on A medium (soluble
starch 1%, corn steep powder 0.25%, yeast extract 0.3%, CaCO3 0.3%,
FeSO4 0.0012%, agar 3% [pH 7.0], adjusted with KOH) with addition of
10 mM MgCl2 solution. To select the recombinant progeny by their apramy-
cin-sensitive phenotype, single colonies on A plates were patched in parallel
onto antibiotic (25 mg/ml apramycin)-containing A medium and antibiotic-
free A medium. The desired in-frame deletion mutants were identified by
PCR using the checking primers and further confirmed by Southern blot anal-
ysis (Figures S1A, S1B, S1E, and S1F). Double in-frame deletion mutants,
DgenD2DgenK and DgenS2DgenK, were prepared using the same protocol
with DgenD2 and plasmids pWHU1 (Figures S1C and S1D).
Gene Complementation of the DgenD2, DgenS2, DgenN, DgenD1,
DgenD2DgenK, and DgenS2DgenK Mutants
The complementation plasmids were introduced individually into DgenD2
(pWHU184), DgenS2 (pWHU115), DgenN (pWHU68), DgenD1 (pWHU66),
DgenD2DgenK (pWHU67), and DgenS2DgenK (pWHU67) by conjugation.
Complemented exconjugants were identified based on thiostrepton resis-
tance and confirmed by PCR (Figures S1G–S1L).
Cloning of genD1, genD2, genN, and genS2 Genes for Expression in
E. coli
The genD2, genS2, genN, and genD1 genes were each amplified from the
genomic DNA ofM. echinospora ATCC15835 by PCR using PfuDNA polymer-
ase with 25 cycles of denaturing at 94C for 1 min, annealing at 60C for 1 min,
and extension at 72C for 2 min plus a final extension at 72C for 10 min. The
PCR products were digested with appropriate restriction enzymes, purified
by gel extraction (Fermentas), and inserted into a pET28a(+) plasmid. The
resulting constructs were verified by DNA sequencing.
Overexpression and Purification of Recombinant Proteins
E. coli BL21(DE3) cells bearing the recombinant plasmids were cultured in LB
broth containing kanamycin (50 mg/ml) at 37C until the cell density reached
0.5–1.0 at 600 nm.Overexpression of the proteins was induced by isopropylth-
iogalactoside (IPTG) (0.1 mM) at 20C with shaking at 180 rpm overnight. For
overexpression of GenD1, E. coli BL21(DE3) cells harboring both genD1 gene
in pET28a(+) plasmid and pDB1282 plasmid containing the iron-sulfur cluster
biosynthetic genes (Zheng et al., 1998) were incubated in 1.5 l of LB broth con-
taining kanamycin and carbenicillin in a 2 l flask at 37C, 150 rpm until the cell
density reached A600 = 0.8 – 1.0. The iron-sulfur cluster protein expression was
induced with 20mM L-(+)-arabinose and the culture incubated for a further 45–
60 min. The culture was then cooled to room temperature before addition of
0.2 mM IPTG to induce GenD1 protein expression at 20C, 150 rpm overnight;
2 mM Fe(II)SO4 was also added at this point. Cells were harvested by centrifu-
gation and resuspended in Binding Buffer (0.5 M NaCl, 20 mM Tris-HCl
[pH 7.9]). The Binding Buffer for GenD1 resuspension was purged with N2
for at least 30 min before use. The recombinant protein was released by son-
ication for 4 min using a 2 s on/6 s off cycle and the recombinant protein in the
clarified cell lysate was purified using Co2+ or Ni2+ ion-charged His-Bind metal
chelating resin (Novagen) according to the manufacturer’s instructions. Imid-
azole in the eluted GenD2, GenS2, and GenN solutions was removed by buffer
exchange using Amicon Ultra centrifugal filters (Millipore). The purification& Biology 22, 251–261, February 19, 2015 ª2015 The Authors 259
procedure for GenD1 from the His-Bind purification and onward was carried
out in a DAB-10S anaerobic chamber (Saffron Scientific). Imidazole was
removed from the purified GenD1 protein solution using a PD10 column
(GE Healthcare) with a buffer containing 0.25 M NaCl and 20 mM Tris-HCl
(pH 7.9). Anaerobic buffers were prepared outside the anaerobic chamber
and autoclaved. Autoclaved buffers were then purged with nitrogen for at least
30 min with stirring before being transferred to the anaerobic chamber, and
allowed to stir uncapped at least overnight. Chemical solutions to be stored
at 20C were prepared within the anaerobic chamber and transferred
immediately to 20C after removal from the anaerobic chamber. Chemical
solutions freshly prepared on the day of use were dissolved in anaerobic water
inside the anaerobic chamber. Tips, tubes, and other consumables were
autoclaved and stored in the anaerobic chamber.
The purified proteins were stored at 20C in a buffer containing 250 mM
NaCl, 10 mM Tris-HCl (pH 7.9), and 33% glycerol. The identities of the purified
recombinant proteins were confirmed by SDS-PAGE, UV-visible absorbance
analysis (Cary 100 Bio UV-visible spectrophotometer), and LC-ESI-MS
(ThermoFinnigan). Protein concentrations were determined using Bradford
protein dye reagent (Sigma).
Reconstitution of the Iron-Sulfur Cluster in GenD1
The reconstitution of the iron-sulfur cluster in GenD1 protein was conducted
under strictly anaerobic conditions immediately after elution from PD-10 col-
umns. The average temperature in the glove box was 30C. The protein solu-
tion (2.5 ml) was incubated with 5 mM DTT for 15 min followed by addition of
1mMFe(II)(NH4)2(SO4)2 and 1mMNa2S, both were freshly prepared, yielding a
translucent, blackish solution. The solution was left at room temperature for
1 hr, and was then exchanged into a buffer containing 0.25 M NaCl and
20 mM Tris-HCl (pH 7.9) using a PD-10 column. The eluted protein solution re-
mained grayish black, indicating a successful reconstitution. A portion of the
reconstituted protein was transferred to a quartz cuvette with a lid and sealed
with Parafilm, and was immediately subjected to UV-vis scanning. The recon-
stituted protein was stored at80C, in Eppendorf tubes wrapped in Parafilm,
after addition of glycerol to 33% (v/v).
Activity Assays of GenD2, GenS2, and GenN
Gentamicin A2 (3) purified from the DgenS2DgenK mutant of M. echinospora
ATCC15835 (see Supplemental Experimental Procedures, Method S1, for
the protocol of purification) was used as a substrate in assays testing the
activity of GenD2 as a 300-dehydrogenase, GenS2 as a 300-transaminase, and
GenN as a 300-N-methyltransferase. A typical reaction (100 ml) contained sub-
strate (400 mM), NAD+ or NADP+ (2.5 mM), L-glutamate (1 mM, when GenS2
was present), SAM (2 mM, when GenN was present), and purified enzyme(s)
(30 mM each) in Tris-HCl buffer (50 mM, pH 7.5). To test the deamination activ-
ity of GenS2 and the subsequent ketoreductase activity of GenD2 (the reverse
reactions), kanamycin B (11) and tobramycin (12) were used as substrates. A
typical reaction mixture consisted of substrate (400 mM), NADH or NADPH
(2.5 mM), 2-oxoglutarate (1 mM, when GenS2 was present), and purified en-
zyme(s) (30 mM) in Tris-HCl buffer (50 mM, pH 7.5). Kanamycin and tobramycin
were used as substrate analogs to test the putative 300-N-methyltransferase
activity of GenN. A typical reaction mixture contained substrate (400 mM),
SAM (2 mM), and purified GenN (30 mM) in Tris-HCl buffer (50 mM, pH 7.5).
Reaction mixtures were incubated at 30C and quenched by addition of
chloroform (100 ml) followed by vigorous vortexing. Precipitated protein was
removed by centrifugation. Ten to twenty microliters of the aqueous superna-
tant were analyzed by either LC-ESI-MS or LC-ESI-HRMS.
GenD1 Assay
Assays were carried out in an anaerobic chamber (30C) overnight. Standard
reaction mixtures (50 ml) contained 1 mM MeCbl, 10 mM DTT, 4 mM SAM,
100 mM purified reconstituted GenD1, 400 mM substrate, 4 mM NADPH, and
1 mM MV in 50 mM Tris-HCl (pH 8). Alternative reducing agents tested were
combinations of 4 mM NADPH or Na2S2O4 and 1 mMMV or BV. After incuba-
tion, assays were removed from the anaerobic chamber and protein was
precipitated by addition of 50 ml of chloroform. The assays were vortexed
and then centrifuged at 13,000 rpm for 5 min. Ten to twenty microliters of
the aqueous supernatant were analyzed by either LC-ESI-MS or LC-ESI-
HRMS.260 Chemistry & Biology 22, 251–261, February 19, 2015 ª2015 TheLC-ESI-MS Analyses
Conditions for LC-ESI-MS analyseswere as described in Supplemental Exper-
imental Procedures.
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